Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Swiss-listed BB Biotech marks 30 years of outperformance with fund manager Dr. Daniel Koller confident the recent biotechnology slump will in time look like a small setback.

This crash will look like a blip

Swiss-listed BB Biotech marks 30 years of outperformance with fund manager Dr. Daniel Koller confident the recent biotechnology slump will in time look like a small setback.
05.12.2023 - Daniel Koller